Yuuth
Pre-clinical- Indications
- Skin aging, UV-damaged skin
Company intelligence / Profile preview
Ponce Therapeutics
Houston, Texas, United Statesponcetherapeutics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Developing anti-aging products with scientific basis, including a lead senolytic skin care product (Yuuth™) that delivers proprietary senolytic peptide PTC-2101 topically to arrest or reverse aging effects
- Therapeutic areas
- OtherDermatology
- Modalities
- PeptidesGene therapyNanoparticle technologies
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Speratum Biopharma (licensed their Nano-in™ and No-Pass Mimic™ Nanoparticle Technologies)
Beyond the preview
Go deeper on Ponce Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ponce Therapeutics.